These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23348588)

  • 21. Imatinib prevents dexamethasone-induced pancreatic β-cell apoptosis via decreased TRAIL and DR5.
    Kutpruek S; Suksri K; Maneethorn P; Semprasert N; Yenchitsomanus PT; Kooptiwut S
    J Cell Biochem; 2023 Sep; 124(9):1309-1323. PubMed ID: 37555250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms.
    Charette N; De Saeger C; Horsmans Y; Leclercq I; Stärkel P
    Cell Death Dis; 2013 Jan; 4(1):e471. PubMed ID: 23348585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells.
    Szliszka E; Helewski KJ; Mizgala E; Krol W
    Int J Oncol; 2011 Oct; 39(4):771-9. PubMed ID: 21743964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation.
    Moon DO; Kim MO; Choi YH; Kim GY
    Mol Cancer Ther; 2010 Jun; 9(6):1583-95. PubMed ID: 20515942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosis.
    Szliszka E; Zydowicz G; Mizgala E; Krol W
    Int J Oncol; 2012 Sep; 41(3):818-28. PubMed ID: 22735465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
    Chen X; Kandasamy K; Srivastava RK
    Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL.
    Grunert M; Gottschalk K; Kapahnke J; Gündisch S; Kieser A; Jeremias I
    Cell Death Dis; 2012 Oct; 3(10):e414. PubMed ID: 23096115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-6 sensitizes TNF-α and TRAIL/Apo2L dependent cell death through upregulation of death receptors in human cancer cells.
    Sano E; Kazaana A; Tadakuma H; Takei T; Yoshimura S; Hanashima Y; Ozawa Y; Yoshino A; Suzuki Y; Ueda T
    Biochim Biophys Acta Mol Cell Res; 2021 Jun; 1868(7):119037. PubMed ID: 33839168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.
    Brost S; Zimmermann A; Koschny R; Sykora J; Stremmel W; Schirmacher P; Walczak H; Ganten TM
    Pathol Res Pract; 2014 Feb; 210(2):83-91. PubMed ID: 24268735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor necrosis factor-alpha induces caspase-mediated cleavage of peroxisome proliferator-activated receptor gamma in adipocytes.
    Guilherme A; Tesz GJ; Guntur KVP; Czech MP
    J Biol Chem; 2009 Jun; 284(25):17082-17091. PubMed ID: 19321447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells.
    Ivanov VN; Zhou H; Partridge MA; Hei TK
    Cancer Res; 2009 Apr; 69(8):3510-9. PubMed ID: 19351839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
    Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
    Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional roles of tumor necrosis factor-related apoptosis-inducing ligand-DR5 interaction in B16F10 cells by activating the nuclear factor-κB pathway to induce metastatic potential.
    Takahashi K; Takeda K; Saiki I; Irimura T; Hayakawa Y
    Cancer Sci; 2013 May; 104(5):558-62. PubMed ID: 23347256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells.
    Morello S; Sorrentino R; Porta A; Forte G; Popolo A; Petrella A; Pinto A
    J Cell Physiol; 2009 Nov; 221(2):378-86. PubMed ID: 19562684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases.
    Audo R; Combe B; Coulet B; Morel J; Hahne M
    Cell Death Differ; 2009 Sep; 16(9):1227-37. PubMed ID: 19407827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
    Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
    Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
    Song JH; Kandasamy K; Kraft AS
    J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Death receptor 5 is activated by fucosylation in colon cancer cells.
    Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
    FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
    Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
    Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.
    Tazzari PL; Tabellini G; Ricci F; Papa V; Bortul R; Chiarini F; Evangelisti C; Martinelli G; Bontadini A; Cocco L; McCubrey JA; Martelli AM
    Cancer Res; 2008 Nov; 68(22):9394-403. PubMed ID: 19010914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.